LENZ Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Stockholders' Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity | ||||||||||
| Shares · Amount | ||||||||||
| Balance as of December 31, 2025 | 31,344,782 | $1 | $511,237 | $(227,141) | $242 | $284,339 | ||||
| Exercise of stock options | 2,698 | — | 14 | — | — | 14 | ||||
| Unrealized loss on marketable securities | — | — | — | — | (692) | (692) | ||||
| Vesting of restricted stock units | 6,914 | — | — | — | — | — | ||||
| Share-based compensation | — | — | 4,319 | — | — | 4,319 | ||||
| Net loss | — | — | — | (41,488) | — | (41,488) | ||||
| Balance as of March 31, 2026 | 31,354,394 | $1 | $515,570 | $(268,629) | $(450) | $246,492 | ||||
| Unrealized loss on marketable securities | — | — | — | — | (179) | (179) | ||||
| Share-based compensation | — | — | 4,472 | — | — | 4,472 | ||||
| Issuance of common stock under employee stock purchase plan | 62,498 | — | 395 | — | — | 395 | ||||
| Net loss | — | — | — | (31,918) | — | (31,918) | ||||
| Balance as of June 30, 2026 | 31,416,892 | $1 | $520,437 | $(300,547) | $(629) | $219,262 | ||||
| Stockholders' Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity | |||||||||||
| Shares · Amount | |||||||||||
| Balance as of December 31, 2024 | 27,518,439 | $1 | $348,901 | $(145,014) | $196 | $204,084 | |||||
| Exercise of stock options | 11,630 | — | 44 | — | — | 44 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (73) | (73) | |||||
| Vesting of early exercised stock options | 5,594 | — | 19 | — | — | 19 | |||||
| Share-based compensation | — | — | 2,555 | — | — | 2,555 | |||||
| Net loss | — | — | — | (14,619) | — | (14,619) | |||||
| Balance as of March 31, 2025 | 27,535,663 | $1 | $351,519 | $(159,633) | $123 | $192,010 | |||||
| Exercise of stock options | 29,003 | — | 196 | — | — | 196 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (85) | (85) | |||||
| Vesting of early exercised stock options | 5,593 | — | 19 | — | — | 19 | |||||
| Share-based compensation | — | — | 2,845 | — | — | 2,845 | |||||
| Issuance of common stock through at-the-market offerings, net of issuance costs | 920,500 | — | 26,067 | — | — | 26,067 | |||||
| Exercise of stock warrant | 271 | — | — | — | — | — | |||||
| Issuance of common stock under employee stock purchase plan | 9,092 | — | 225 | — | — | 225 | |||||
| Net loss | — | — | — | (14,912) | — | (14,912) | |||||
| Balance as of June 30, 2025 | 28,500,122 | $1 | $380,871 | $(174,545) | $38 | $206,365 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.